Goldman Sachs
UTHR icon

Goldman Sachs’s United Therapeutics UTHR Stock Holding History

Goldman Sachs’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,300
Closed -$2.22M – 6841
2025
Q3 		$2.22M Sell
5,300
-64,700
-92% -$21.8M ﹤0.01% 4378
2025
Q2 		$20.1M Buy
70,000
+67,100
+2,314% +$20.1M ﹤0.01% 2124
2025
Q1 		$894K Buy
+2,900
New +$994K ﹤0.01% 4768
2021
Q3 		– Sell
-10,000
Closed -$1.79M – 6532
2021
Q2 		$1.79M Buy
+10,000
New +$1.9M ﹤0.01% 4305
2020
Q2 		– Sell
-25,000
Closed -$2.37M – 5494
2020
Q1 		$2.37M Buy
+25,000
New +$2.38M ﹤0.01% 3176
2018
Q1 		– Sell
-700
Closed -$104K – 6418
2017
Q4 		$104K Sell
700
-19,400
-97% -$2.47M ﹤0.01% 5727
2017
Q3 		$2.36M Buy
20,100
+19,400
+2,771% +$2.48M ﹤0.01% 3831
2017
Q2 		$91K Sell
700
-251,900
-100% -$31.4M ﹤0.01% 6157
2017
Q1 		$34.2M Buy
252,600
+246,400
+3,974% +$37.3M 0.01% 1490
2016
Q4 		$889K Sell
6,200
-5,900
-49% -$753K ﹤0.01% 4559
2016
Q3 		$1.43M Buy
12,100
+6,500
+116% +$781K ﹤0.01% 4091
2016
Q2 		$593K Sell
5,600
-26,400
-83% -$2.94M ﹤0.01% 4692
2016
Q1 		$3.57M Sell
32,000
-300
-0.9% -$38K ﹤0.01% 2981
2015
Q4 		$5.06M Buy
32,300
+17,600
+120% +$2.56M ﹤0.01% 2821
2015
Q3 		$1.93M Sell
14,700
-22,900
-61% -$3.67M ﹤0.01% 3833
2015
Q2 		$6.54M Buy
37,600
+20,900
+125% +$3.76M ﹤0.01% 2705
2015
Q1 		$2.88M Buy
16,700
+7,600
+84% +$1.16M ﹤0.01% 3431
2014
Q4 		$1.18M Sell
9,100
-106,000
-92% -$13.7M ﹤0.01% 4395
2014
Q3 		$14.8M Buy
115,100
+13,800
+14% +$1.42M ﹤0.01% 2039
2014
Q2 		$8.96M Buy
101,300
+94,000
+1,288% +$9.04M ﹤0.01% 2462
2014
Q1 		$686K Sell
7,300
-10,700
-59% -$1.09M ﹤0.01% 5003
2013
Q4 		$2.04M Buy
18,000
+8,800
+96% +$794K ﹤0.01% 4040
2013
Q3 		$725K Sell
9,200
-11,100
-55% -$811K ﹤0.01% 4849
2013
Q2 		$1.34M Buy
+20,300
New +$1.31M ﹤0.01% 4133

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Goldman Sachs's UTHR Position: Q1 2026 in Review

Goldman Sachs increased its United Therapeutics (UTHR) stake by 3.3% in Q1 2026, buying an estimated $1.82M and bringing the position to 114,419 shares worth $67.8M. The position accounts for 0.01% of the portfolio, ranked #1328.

Goldman Sachs first reported a position in UTHR in Q2 2013 and has held it in 52 quarters since. The position peaked at $204M in Q2 2017. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Goldman Sachs held 114,419 shares of United Therapeutics worth $67.8M as of Q1 2026.
  • Goldman Sachs bought 3,645 United Therapeutics shares in Q1 2026, an estimated $1.82M.
  • United Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1328 holding.
  • Goldman Sachs first reported a position in United Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's United Therapeutics position peaked at $204M in Q2 2017.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.